Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Clinical trial NCT02938793 · TERMINATED

Trial details

NCT number: NCT02938793
Sponsor: Prisma Health-Upstate
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Cancer Rare Disease

Start date: 2016-12-01
Primary completion: 2025-09-17
Enrollment: 92

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.